Ignite Creation Date:
2024-05-06 @ 2:18 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04278222
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2020-02-19
Brief Title:
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 APICAL-GC
Sponsor:
Shanghai Changzheng Hospital
Organization:
Shanghai Changzheng Hospital
Organization Data
Organization:
Shanghai Changzheng Hospital
Class:
OTHER
Study ID:
APICAL-GC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Changzheng Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Yuan-Sheng Zang
Responsible Party Title:
Director
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shanghai Changzheng Hospital
Old Name:
None
Old Organization:
None